-$0.34 EPS Expected for Nightstar Therapeutics PLC (NITE) This Quarter
Brokerages predict that Nightstar Therapeutics PLC (NASDAQ:NITE) will post ($0.34) earnings per share for the current quarter, Zacks reports. Zero analysts have made estimates for Nightstar Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.27) and the lowest estimate coming in at ($0.40). The firm is scheduled to issue its next quarterly earnings results on Tuesday, April 2nd.
On average, analysts expect that Nightstar Therapeutics will report full-year earnings of ($1.45) per share for the current financial year, with EPS estimates ranging from ($1.77) to ($1.25). For the next year, analysts forecast that the company will post earnings of ($1.53) per share, with EPS estimates ranging from ($1.93) to ($1.27). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Nightstar Therapeutics.
NITE has been the subject of several research analyst reports. Barclays initiated coverage on Nightstar Therapeutics in a research note on Monday, December 17th. They issued an “overweight” rating and a $28.00 price objective for the company. Zacks Investment Research upgraded Nightstar Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, November 15th. UBS Group initiated coverage on Nightstar Therapeutics in a research note on Friday, January 4th. They issued a “buy” rating and a $21.00 price objective for the company. Cantor Fitzgerald restated a “buy” rating and issued a $42.00 price objective on shares of Nightstar Therapeutics in a research note on Thursday, January 31st. Finally, ValuEngine upgraded Nightstar Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday. Eleven equities research analysts have rated the stock with a buy rating, Nightstar Therapeutics has an average rating of “Buy” and an average target price of $31.00.
In related news, insider Gregory Scott Robinson sold 14,764 shares of Nightstar Therapeutics stock in a transaction that occurred on Wednesday, January 2nd. The stock was sold at an average price of $11.15, for a total transaction of $164,618.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO David A. Fellows sold 8,733 shares of Nightstar Therapeutics stock in a transaction that occurred on Monday, January 7th. The shares were sold at an average price of $12.98, for a total value of $113,354.34. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 24,328 shares of company stock valued at $291,734.
A number of hedge funds have recently made changes to their positions in NITE. Bank of America Corp DE purchased a new position in Nightstar Therapeutics during the second quarter valued at approximately $132,000. Harel Insurance Investments & Financial Services Ltd. purchased a new position in Nightstar Therapeutics during the third quarter valued at approximately $169,000. Janney Montgomery Scott LLC purchased a new position in Nightstar Therapeutics during the third quarter valued at approximately $204,000. JPMorgan Chase & Co. purchased a new position in Nightstar Therapeutics during the third quarter valued at approximately $214,000. Finally, Monashee Investment Management LLC purchased a new stake in shares of Nightstar Therapeutics in the third quarter valued at approximately $1,430,000. Institutional investors own 37.66% of the company’s stock.
About Nightstar Therapeutics
Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia.
Featured Article: Roth IRA
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.